Study of who develops carbapenem-resistant infections in PICU children
Part of Infections clinical trials.
This study looks at factors that make some hospitalized children in the pediatric intensive care unit (PICU) develop or carry germs called carbapenem-resistant Enterobacteriaceae. It aims to understand who is at higher risk and why, which may help prevent infections in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a child admitted to the PICU at Children’s Hospital of Fudan University between Jan 2018 and Dec 2019
- Stay in the hospital at least 48 hours after admission
- Do not have a positive test for CRE (carbapenem-resistant germs) before being admitted
- Have complete clinical and basic demographic information available
- (If applicable) You were hospitalized during the study dates at this specific hospital
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at patients who have severe infections caused by carbapenem-resistant Enterobacterales (CRE), which are bacteria that are hard to treat because they resist many antibiotics. It will examine the germs and how patients respond to newer antibiotics that are specifically used for these tough infections.
This study tests ways to reduce how a hard-to-treat bacterial germ spreads between hospitals, homes, communities, and animals. It focuses on children under 2 years old in the selected hospital area because they may be more likely to pick up and spread the bacteria.
This trial tests whether measuring drug levels in the blood can help doctors give the right dose of ceftazidime-avibactam (an antibiotic) to patients with hard-to-treat infections in the ICU, potentially improving treatment outcomes and reducing side effects.
This trial tests a medicine called colistimethate sodium for people in the hospital with a serious infection (pneumonia or bloodstream infection) caused by a resistant bacteria called CRE. The goal is to see if this antibiotic can effectively treat the infection.
This trial enrolls children in the pediatric intensive care unit (PICU) who have a severe infection. It aims to better understand germs and drug resistance so future treatments can be more effective.
This study looks at whether patients in the intensive care unit (ICU) carry certain hard-to-treat bacteria (carbapenem-resistant enterobacteriaceae, or CRE) in their gut. By finding out how common this is, doctors can better protect patients from infections.
Hear when a new Carbapenem-Resistant Enterobacteriaceae Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.